MENU
+Compare
XGN
Stock ticker: NASDAQ
AS OF
Jan 23, 10:44 AM (EDT)
Price
$4.05
Change
+$0.01 (+0.25%)
Capitalization
27.06M

XGN Exagen Forecast, Technical & Fundamental Analysis

a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases

XGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for XGN with price predictions
Jan 08, 2025

XGN in upward trend: price may jump up because it broke its lower Bollinger Band on January 02, 2025

XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 42 cases where XGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XGN's RSI Oscillator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 119 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 26, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on XGN as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

XGN moved below its 50-day moving average on January 02, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.192) is normal, around the industry mean (23.424). P/E Ratio (0.000) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.528) is also within normal values, averaging (41.167).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
XGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

XGN is expected to report earnings to rise 12.61% to -31 cents per share on March 24

Exagen XGN Stock Earnings Reports
Q4'24
Est.
$-0.32
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.18
Q1'24
Beat
by $0.17
Q4'23
Beat
by $0.12
The last earnings report on November 12 showed earnings per share of -28 cents, beating the estimate of -28 cents. With 4.19K shares outstanding, the current market capitalization sits at 27.06M.
A.I. Advisor
published General Information

General Information

a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
N/A
Address
1261 Liberty Way
Phone
+1 760 560-1501
Employees
179
Web
https://www.exagen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
COEP10.801.29
+13.56%
Coeptis Therapeutics Holdings Inc
VLY9.80-0.04
-0.41%
Valley National Bancorp
GRMN216.20-1.62
-0.74%
Garmin Ltd
CIM14.28-0.16
-1.11%
Chimera Investment Corp
TDUP2.20-0.06
-2.65%
ThredUp

XGN and Stocks

Correlation & Price change

A.I.dvisor tells us that XGN and DRIO have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XGN and DRIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XGN
1D Price
Change %
XGN100%
+0.75%
DRIO - XGN
24%
Poorly correlated
+6.31%
NTRA - XGN
24%
Poorly correlated
+2.67%
INGN - XGN
23%
Poorly correlated
-3.22%
BIOQ - XGN
23%
Poorly correlated
-0.80%
OPK - XGN
23%
Poorly correlated
-2.00%
More